Top Markets
Coin of the day
GlycoNex Incorporation GlycoNex Incorporation

GlycoNex Incorporation

4168
Peringkat dalam Saham #22943
GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in... GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipeline for solid tumors features several investigational antibody drugs. These include GNX102, a humanized monoclonal antibody currently in Phase 1 clinical trials; GNX201, an antibody candidate undergoing lead optimization; and GNX202, which is in preclinical development. Additionally, GNX203 and GNX204 are antibody drugs presently in the target validation stage. Beyond oncology, GlycoNex is also advancing other therapeutic agents. This includes SPD (Denosumab), a humanized IgG2 antibody in preclinical stages for both osteoporosis and oncology indications. Another key asset is SEA (Aflibercept), a vascular endothelial growth factor (VEGF) binding fusion protein, currently undergoing lead optimization for its potential use in ophthalmology and oncology. GlycoNex was established in 2001.
Harga Saham
$0.71865803
Terakhir disinkronkan: 2026-08-21
Kapitalisasi Pasar
$80.86M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-5.48%
Negara
TW
Perdagangan GlycoNex Incorporation (4168)

Kategori

Rasio P/B untuk GlycoNex Incorporation (4168)
Rasio P/B per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari GlycoNex Incorporation, rasio P/B saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/B perusahaan adalah 0.
Riwayat rasio P/B untuk GlycoNex Incorporation dari 2026 hingga 2026
Rasio P/B pada akhir setiap tahun
Tahun Rasio P/B Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/B untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/B Perbedaan Rasio P/B Negara
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH